Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03952234 · ClinicalTrials.gov registry record · Phase 1
L-Citrulline Dose Finding Safety Study in MELAS
A Phase 1 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03952234 is a Phase 1 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 10 participants.
The verdict
NCT03952234, a Phase 1 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the safest maximum dose of an amino acid, citrulline, which will be used as potential treatment for adult patients with a disorder of energy metabolism called Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). Once established, this dose will be used in a future clinical trial.
Interventions
- DRUG L-Citrulline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-04-22 |
| Est. Completion | 2024-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03952234
The ClinicalTrials.gov registry entry for NCT03952234 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which L-Citrulline is the first listed.
NCT03952234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03952234 about?
NCT03952234 is a clinical study titled "L-Citrulline Dose Finding Safety Study in MELAS". The main purpose of this study is to determine the safest maximum dose of an amino acid, citrulline, which will be used as potential treatment for adult patients with a disorder of energy metabolism called Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). Once estab...
What is the current status of trial NCT03952234?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2021-04-22. Estimated completion is 2024-06-01.
What interventions are being tested in trial NCT03952234?
The interventions under investigation include: L-Citrulline (DRUG).
Who is sponsoring clinical trial NCT03952234?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.